GSK vs Gilead: Heavyweight HIV fight will come down to a big showdown in Amsterdam next month
One of the most intense rivalries in biopharma R&D today centers on the showdown between GlaxoSmithKline and Gilead in HIV.
Gilead has dominated the sector for years, keeping a steady hand on the market and developing new and better therapies, like the blockbuster-to-be triple drug Biktarvy. But GlaxoSmithKline has enjoyed some big advances of its own at its majority-owned ViiV, and now analysts expect the intense rivalry to come down to the upcoming International AIDS Conference in Amsterdam on July 24.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.